Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference

Rhea-AI Summary

Radiopharm Theranostics (RADX), a clinical-stage biopharmaceutical company specializing in oncology radiopharmaceuticals, has announced its participation in the upcoming D. Boral Capital Inaugural Global Conference. The event is scheduled for May 14, 2025, in New York City. The company's management team will be available for one-on-one meetings with interested parties, who can arrange meetings by contacting John Perez at jperez@dboralcapital.com. Radiopharm focuses on developing innovative treatments for areas with high unmet medical needs in oncology.

News Market Reaction – RADX

+3.33%

+3.33% Session move

In the trading session that priced this news, RADX gained 3.33%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SYDNEY, May 07, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that members of management will be participating in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City.

To register for one-on-one meetings with management in New York City, interested parties should contact John Perez at jperez@dboralcapital.com.

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain. Learn more at radiopharmtheranostics.com.

Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.

For more information:

Investors:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Anne Marie Fields
Precision AQ (formerly Stern IR)
E: annemarie.fields@precisionaq.com

Media:
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
X – https://x.com/TeamRadiopharm  
LinkedIn – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/

FAQ

When is Radiopharm Theranostics (RADX) participating in the D. Boral Capital Conference?

Radiopharm Theranostics will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City.

How can investors meet with Radiopharm Theranostics management at the D. Boral Capital Conference?

Interested parties can arrange one-on-one meetings with management by contacting John Perez at jperez@dboralcapital.com.

What is Radiopharm Theranostics (RADX) main business focus?

Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need.

Which stock exchanges is Radiopharm Theranostics listed on?

Radiopharm Theranostics is listed on both the Australian Securities Exchange (ASX:RAD) and the Nasdaq (RADX).